Targeting IL-23 in psoriasis: current perspectives.
Title | Targeting IL-23 in psoriasis: current perspectives. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Fotiadou, C., Lazaridou E., Sotiriou E., & Ioannides D. |
Journal | Psoriasis (Auckl) |
Volume | 8 |
Pagination | 1-5 |
Date Published | 2018 |
ISSN | 2230-326X |
Abstract | The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors. |
DOI | 10.2147/PTT.S98893 |
Alternate Journal | Psoriasis (Auckl) |
PubMed ID | 29441315 |
PubMed Central ID | PMC5804022 |